178 related articles for article (PubMed ID: 22293705)
1. [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
Okazaki K; Watanabe T; Saito I; Murayama J
Yakugaku Zasshi; 2012; 132(2):231-6. PubMed ID: 22293705
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
3. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H
Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652
[TBL] [Abstract][Full Text] [Related]
4. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
[TBL] [Abstract][Full Text] [Related]
7. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
9. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR
Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783
[TBL] [Abstract][Full Text] [Related]
10. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
[TBL] [Abstract][Full Text] [Related]
11. [Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
Ma L; Chen Y; Yang C; Jiang H; Zhu J; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):29-32. PubMed ID: 25877315
[TBL] [Abstract][Full Text] [Related]
12. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
Dias MM; McKinnon RA; Sorich MJ
Pharmacogenomics; 2012 Jun; 13(8):889-99. PubMed ID: 22676194
[TBL] [Abstract][Full Text] [Related]
13. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
14. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
15. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
16. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Peng H; Duan Z; Pan D; Wen J; Wei X
Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
[TBL] [Abstract][Full Text] [Related]
17. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
[TBL] [Abstract][Full Text] [Related]
18. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
Cruz JE; Saksena R; Jabbour SK; Nosher JL; Hermes-DeSantis E; Moss RA
Ann Pharmacother; 2014 Dec; 48(12):1646-50. PubMed ID: 25202035
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
[TBL] [Abstract][Full Text] [Related]
20. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR
World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
